...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Vaccine >Post-licensure monitoring of HPV vaccine in the United States
【24h】

Post-licensure monitoring of HPV vaccine in the United States

机译：在美国对HPV疫苗进行许可后监测

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Post-licensure evaluation of vaccines plays an important role in monitoring the progress of immunization programs, demonstrating population impact of vaccines, and providing data for ongoing policy decisions. Two human papillomovirus (HPV) vaccines are licensed and recommended for use in females in the United States, a quadrivalent human HPV vaccine, licensed in 2006 and a bivalent vaccine HPV vaccine licensed in 2009. HPV vaccination is recommended for females 11 or 12 years of age with catch-up vaccination through age 26 years. Post-licensure monitoring of the HPV vaccine program has included some of the same systems established for other vaccines, such as those for vaccine safety and coverage monitoring. However, monitoring HPV vaccine impact on infection and disease outcomes has required new efforts. While there are well established cancer registries in the United States, it will take decades before the impact of vaccine on cervical cancer is observed. More proximal measures of vaccine impact include outcomes such as prevalence of HPV vaccine types, incidence of cervical precancers and genital warts. We review systems in place or being established for post-licensure monitoring of HPV vaccine in the United States
机译：疫苗的许可后评估在监测免疫程序的进展，证明疫苗对人群的影响以及为正在进行的政策决策提供数据方面起着重要作用。两种人乳头瘤病毒（HPV）疫苗已获许可并建议在美国女性中使用，四价人HPV疫苗于2006年获得许可，而二价疫苗HPV疫苗于2009年获得许可。建议对11岁或12岁的女性接种HPV疫苗年龄到26岁为止。 HPV疫苗计划的许可后监测包括为其他疫苗建立的某些相同系统，例如用于疫苗安全性和覆盖率监测的系统。但是，监测HPV疫苗对感染和疾病结果的影响需要作出新的努力。尽管美国有完善的癌症注册机构，但要花数十年才能观察到疫苗对子宫颈癌的影响。疫苗影响的更近端指标包括诸如HPV疫苗类型的流行率，宫颈癌的发病率和生殖器疣等结局。我们审查在美国针对HPV疫苗进行许可后监控的现有系统或正在建立的系统

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号